- Home
- EIX vs ROIV Comparison
EIX vs ROIV Comparison
Compare EIX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIX | ROIV |
|---|---|---|
| Founded | 1886 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4B | 25.1B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EIX | ROIV |
|---|---|---|
| Price | $55.78 | $41.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $72.09 | $28.94 |
| AVG Volume (30 Days) | 6.1M | ★ 7.9M |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 248.94 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $19,317,000,000.00 | $8,260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.17 | $744.61 |
| P/E Ratio | $41.93 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $52.00 | $13.83 |
| 52 Week High | $81.62 | $42.50 |
Technical Indicators
Market Signals| Indicator | EIX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 66.10 |
| Support Level | N/A | $33.15 |
| Resistance Level | $61.57 | N/A |
| Average True Range (ATR) | 3.16 | 1.37 |
| MACD | -1.09 | 0.53 |
| Stochastic Oscillator | 17.11 | 78.11 |
Price Performance
Historical ComparisonAbout EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.